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Neutralization of ﬂaviviruses requires engagement of the virion by antibodies with a stoichiometry that
exceeds a required threshold. Factors that modulate the number of antibodies bound to an individual
virion when it contacts target cells impact neutralization potency. However, the contribution of cellular
factors to the potency of neutralizing antibodies has not been explored systematically. Here we
investigate the relationship between expression level of a viral attachment factor on cells and the
neutralizing potency of antibodies. Analysis of the attachment factor DC-SIGNR on cells in neutraliza-
tion studies failed to identify a correlation between DC-SIGNR expression and antibody-mediated
protection. Furthermore, neutralization potency was equivalent on a novel Jurkat cell line induced to
express DC-SIGNR at varying levels. Finally, blocking virus-attachment factor interactions had no
impact on neutralization activity. Altogether, our studies suggest that cellular attachment factor
expression is not a signiﬁcant contributor to the potency of neutralizing antibodies to ﬂaviviruses.
& 2012 Elsevier Inc. All rights reserved.Introduction
Flaviviruses are small RNA viruses responsible for considerable
morbidity and mortality worldwide for which vaccines and
therapeutics are badly needed. Members of this genus that cause
severe disease in humans include West Nile virus (WNV), dengue
virus (DENV), yellow fever virus, tick-borne encephalitis virus,
and Japanese encephalitis virus. WNV is a mosquito-born ﬂavi-
virus that circulates in an enzootic cycle between mosquitoes and
birds; a variety of additional vertebrate species have been shown
to represent dead-end hosts for WNV, including humans (Hayes
and Gubler, 2006). WNV was ﬁrst introduced into the Western
Hemisphere in 1999 resulting in 59 hospitalizations with severe
neurologic disease in the New York city area and seven fatalities
(Marﬁn and Gubler, 2001). WNV has since spread across North
America into Canada and Central America (Artsob et al., 2009).
It is estimated that more than three million human WNV infec-
tions have occurred in the United States since its introduction
(Petersen et al., 2012). The majority of human WNV infec-
tions do not cause overt disease. Clinically apparent infections
range from a self-limiting febrile illness to more severe neuro-
logic manifestations that include encephalitis, meningitis, andll rights reserved.
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on).a polio-like paralytic syndrome (Sejvar, 2007). At present, treat-
ment of WNV infection is limited to supportive measures. Despite
signiﬁcant progress, there is currently no WNV vaccine licensed
for use in humans (reviewed by Beasley (2011)).
Antibodies are a critical component of immunologic protection
from ﬂavivirus infection (reviewed by Dowd and Pierson (2011)).
Passive transfer of antibody has been shown to confer protection
in several animal models of ﬂavivirus infection. Monoclonal
antibodies (mAbs) may also be effective when administered
therapeutically (reviewed by Diamond et al. (2012)). One such
mAb, the WNV-speciﬁc neutralizing mAb E16, is currently being
evaluated in phase I human trials (NCT ID: NCT00927953) (Beigel
et al., 2010; Oliphant et al., 2005). Antibodies have the potential
to contribute to protection from WNV via several mechanisms,
including directly neutralizing virus infectivity (reviewed by
Dowd and Pierson (2011)). This activity can be augmented in an
antibody subclass-dependent manner through interactions
between the complement component C1q and the constant
region of the antibody heavy chain (Fc region) (Mehlhop et al.,
2009). Other Fc-dependent effector functions may also contribute
to protection by a variety of mechanisms, including facilitating
complement deposition on infected cells and antibody-dependent
cellular cytotoxicity (Garcia et al., 2006; Kurane et al., 1984;
Laoprasopwattana et al., 2007).
The primary targets of neutralizing antibodies are the envel-
ope (E) proteins incorporated into the virion (reviewed by Dowd
and Pierson (2011), Roehrig (2003)). The E protein is an elongated
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and their entry into cells (reviewed by Mukhopadhyay et al.
(2005)). Flaviviruses assemble at membranes derived from the
endoplasmic reticulum as immature virions that incorporate 60
heterotrimeric spikes of E proteins in complex with the premem-
brane protein (prM). During egress though the trans-Golgi net-
work, pH-dependent changes in the arrangement of prM and E
allow for cleavage of prM by a cellular furin-like protease (Li et al.,
2008; Stadler et al., 1997; Yu et al., 2008). Cleavage of prM is
required for infectivity of the virion and deﬁnes the maturation
step in the virus lifecycle (Elshuber et al., 2003). E proteins on the
resulting mature virus particle exist as anti-parallel dimers
organized into a dense herringbone arrangement (Kuhn et al.,
2002; Mukhopadhyay et al., 2003; Mukhopadhyay et al., 2005).
How antibodies neutralize virus infection has been studied
extensively. In this regard, one informative perspective is to
consider how the number of antibody molecules bound to the
virion governs its infectivity; stoichiometric models of neutraliza-
tion have been presented for several classes of viruses, including
ﬂaviviruses (reviewed by Della-Porta and Westaway (1978),
Parren and Burton (2001)). Neutralization of ﬂaviviruses is a
‘‘multiple-hit’’ phenomenon that requires engagement of the
virus particle by antibody with a stoichiometry that exceeds a
required threshold (reviewed by Dowd and Pierson (2011)).
Our estimate of this threshold is 30 antibody molecules per
virion (Pierson et al., 2007). Two factors principally govern the
stoichiometry of antibody engagement of the virion at any
particular concentration of antibody: antibody afﬁnity and epi-
tope accessibility (reviewed by Dowd and Pierson (2011)). Both
have been shown to modulate the potency of neutralizing anti-
bodies to ﬂaviviruses (Cherrier et al., 2009; Cockburn et al., 2012;
Gromowski and Barrett, 2007; Gromowski et al., 2008;
Gromowski et al., 2010; Nelson et al., 2008; Nybakken et al.,
2005; Oliphant et al., 2006; Pierson et al., 2007; Stiasny et al.,
2006). Because antibodies bind virions quite rapidly relative to
the rate of virus attachment to cells, the number of antibodies
bound to an individual virion at steady state is likely determined
prior to contact with a target cell (Della-Porta and Westaway,
1978; Dowd et al., 2011; Steckbeck et al., 2005). A role for cellular
factors in determining the neutralization potency of anti-
ﬂavivirus antibodies is not well established, and may not be
predicted solely from this stoichiometric perspective. In this
study, we explore whether differences in the expression level
of a virus attachment factor modulate the neutralization potency
of monoclonal and polyclonal antibodies.Results and discussion
Attachment factor expression correlates with the efﬁciency of WNV
infection on Raji-DCSIGNR cells
The cell biology of ﬂavivirus entry is poorly understood
(reviewed by Fernandez-Garcia et al. (2009)). While several cellular
proteins have been identiﬁed with a capacity to bind ﬂaviviruses,
few have been characterized in detail and shown to be sufﬁcient
for virus attachment and entry (Anderson, 2003). The c-type lectins
DC-SIGN and DC-SIGNR bind several viral pathogens and markedly
increase the efﬁciency of viral infection (reviewed by van Kooyk
and Geijtenbeek (2003)). These attachment proteins recognize the
carbohydrate moieties of N-linked sugars arrayed on the surface of
virions (Davis et al., 2006a; Feinberg et al., 2001); the speciﬁcity
and afﬁnity of these interactions is governed in part by geometrical
orientation of the carbohydrate chains in space (reviewed by
Taylor and Drickamer (2007)). Both DC-SIGN and DC-SIGNR have
been characterized as attachment factors for WNV and DENV(Davis et al., 2006a; Davis et al., 2006b; Dejnirattisai et al., 2011;
Navarro-Sanchez et al., 2003; Tassaneetrithep et al., 2003). While a
role for DC-SIGN or DC-SIGNR in the lifecycle of WNV in vivo has
not been investigated, cells expressing these molecules provide a
reductionist system in which to explore how antibody-mediated
neutralization of infection is modulated by the efﬁciency of virus–
cell interactions. Furthermore, cells expressing c-type lectins are
now commonly used in high-throughput assays of antibody-
mediated neutralization (Balsitis et al., 2010; Boonnak et al.,
2008; Nelson et al., 2008; Pierson et al., 2007; Wahala et al., 2010).
WNV reporter virus particles (RVPs) are pseudo-infectious
virions that allow virus infection to be scored as a function of
reporter gene expression, and have been used extensively to study
virus entry and its inhibition by antibodies (Dowd et al., 2011;
Mehlhop et al., 2009; Nelson et al., 2009; Pierson et al., 2006;
Pierson et al., 2007). The introduction of DC-SIGNR into a cell line
that is poorly permissive for WNV due to an inability to bind virions
(e.g. Raji) markedly increases their permissiveness to infection
(Davis et al., 2006b). To quantify the DC-SIGNR expression level
required for infection, Raji-DCSIGNR cells were incubated with WNV
RVPs and analyzed for virus entry and DC-SIGNR expression two
days post-infection. DC-SIGNR surface expression was quantiﬁed
using a standard curve prepared using QuantumTM Simply Cellular
beads with a known number of antibody binding sites (Bangs
Laboratories, Inc.). A comparison of the DC-SIGNR expression level
of the uninfected Raji cell population to those infected byWNV RVPs
(Fig. 1A) revealed that infection was strongly correlated with high
expression of DC-SIGNR. In agreement, increased expression of
DC-SIGNR correlates with increased susceptibility to WNV infection
(Fig. 1B). Roughly 20,000 DC-SIGNR molecules/cell are required to
support detectable WNV RVP infection using this system.
Impact of attachment factor expression level on antibody-mediated
neutralization of WNV
To investigate the impact of attachment factor expression on
the potency of neutralizing anti-ﬂavivirus antibodies, we pursued
three complementary approaches. We ﬁrst investigated whether
differences in the expression of DC-SIGNR on target cells impact
the concentration of antibody required to inhibit 50% of WNV
infection (EC50). WNV RVPs were incubated with the WNV
domain III lateral-ridge (DIII-LR) speciﬁc mAb E24 for one hour
at 37 1C and then added to Raji-DCSIGNR cells (Oliphant et al.,
2005; Pierson et al., 2007); this incubation has been shown
previously to be sufﬁcient to allow for steady state binding
between antibody and the virion (Dowd et al., 2011). Cells were
harvested two days post-infection and analyzed for GFP and
DC-SIGNR expression using ﬂow cytometry. Analysis of the total
cell population for GFP expression revealed the expected sigmo-
idal neutralization proﬁle for mAb E24 characterized by an EC50 of
3.51011 M (þ/ 4.01012 M, n¼9) (Fig. 2A) (Pierson et al.,
2007). To explore whether DC-SIGNR expression modulated the
potency of E24, the data was re-analyzed by gating on cells
expressing high or low levels of attachment factor as shown in
Fig. 2B. No signiﬁcant difference in the EC50 was detected
between DC-SIGNR high and low expressing cells (n¼9,
p¼0.74) (Figs. 2C and D). Similar results were obtained with the
mAb E53, which binds the structurally distinct domain II fusion
loop (DII-FL) epitope and neutralizes infection by blocking attach-
ment (data not shown, n¼4, p¼0.34) (Nybakken et al., 2005), as
well as polyclonal antibody present in the sera of eight recipients
of a candidate WNV vaccine (Fig. 2E and Fig. S1) (Martin et al.,
2007). Furthermore, neither DC-SIGNR nor DC-SIGN expression
level signiﬁcantly modulated the neutralization sensitivity of
DENV1 RVPs to the type-speciﬁc DIII-reactive mAb E105
(p¼0.86, n¼5; p¼0.49, n¼3, respectively) (Fig. 2F) (Shrestha
Fig. 1. Increased expression of viral attachment factor correlates with increasing
probability of infection. (A) Shown is a contour plot of Raji-DCSIGNR cells infected
with GFP-expressing WNV RVPs and stained with anti-DC-SIGNR antibody. The
percentage of positive cells in each quadrant is indicated. (B) The Raji-DC-SIGNR cells
shown in (A) were divided equally into eight gates based on DC-SIGNR expression
and the percent of GFP positive cells within each gate was determined. These
calculated values were plotted at the median DC-SIGNR expression level of the cells
in each gate. Linear regression analysis of the logarithm of DC-SIGNR expression
(molecules) revealed a strong positive correlation (po0.0001, R2¼0.9834, dashed
gray line). The number of DC-SIGNR molecules was quantiﬁed from a standard curve
generated using beads with deﬁned numbers of antibody-binding sites. Dashed
orange lines represent the 95 percent conﬁdence interval of the linear regression.
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impact of DC-SIGNR expression level on the neutralizing potency
(EC50) of antibodies to WNV or DENV.
WNV infection of Raji-DCSIGNR cells did not signiﬁcantly
impact DC-SIGNR expression as compared to uninfected cells
(when assayed two days post-infection; n¼9, p¼0.15). However,
we could not rule out the possibility that subtle changes in DC-
SIGNR expression might occur during the course of the neutrali-
zation assay and confound our interpretation of the experiments
presented in Fig. 2. Therefore we next created a stable Jurkat cell
line that expresses DC-SIGNR under the control of a tetracycline-
inducible promoter. Jurkat-DC-SIGNR cells become susceptible to
infection only in the presence of tetracycline (Fig. 3A); tetracy-
cline dose-response studies revealed a large range of expression
levels was achievable with saturation occurring at approximately
280,000 DC-SIGNR molecules per cell. To investigate the impact of
differences in DC-SIGNR expression on neutralization potency,
cells were induced to express high, medium, or low levels of
DC-SIGNR (Fig. 3B). Antibody dose response curves were generated
on these populations using mAbs that bind epitopes on each of the
three E protein domains (Fig. 3C–E) and polyclonal antibody froma recipient of a WNV DNA vaccine (Fig. 3F). In each case, neutraliza-
tion activity was not markedly impacted by the level of DC-SIGNR
expressed on the target cell.
Analysis of the distribution of DC-SIGNR on cells infected in the
presence of neutralizing antibodies
To complement our analysis of neutralization potency on cells
that differ with respect to DC-SIGNR expression, we next compared
attachment factor distribution on cells at different points of an
antibody neutralization proﬁle. If the neutralizing potency of an
antibody is truly independent of attachment factor expression on
the target cell, one would expect the distribution of DC-SIGNR
expression to be equivalent among populations infected by WNV
RVPs with or without antibody present. In contrast, if antibody
more effectively prevents infection of cells with low levels of
attachment factor expression, the distribution of DC-SIGNR expres-
sion on cells infected in the presence of antibody would be skewed
towards a higher average number of DC-SIGNR molecules/cell as
compared to cells infected without antibody present. This type of
comparison can be made quantitatively using previously described
chi-squared probability binning analysis described in detail in the
materials and methods section (Roederer et al., 2001).
WNV RVPs were incubated with E24 at the EC50 (Fig. 4A, Box 2)
or a non-neutralizing antibody concentration (Fig. 4A, Box 1) and
added to Raji-DCSIGNR cells. On day two post-infection, cells
were harvested and analyzed for GFP and DC-SIGNR expression.
Histograms that describe the distribution of DC-SIGNR expression
on cells infected (GFPþ) in the presence of neutralizing and non-
neutralizing concentrations of E24 were compared; no difference
was observed (Fig. 4B). As a positive control for this method of
analysis, we repeated this experiment using K562-DCSIGNR cells
that express an activating Fc-receptor that provides a DC-SIGNR-
independent entry pathway in the presence of antibody (Davis
et al., 2006b; Pierson et al., 2007). Antibody dependent enhance-
ment (ADE) of infection describes a marked increase in the
efﬁciency of virus infection in the presence of antibody that is
mediated by Fc-receptors (Fig. 4C) (reviewed by Halstead (2003)).
Previous studies using cell lines and primary dendritic cells
revealed the magnitude of ADE correlates inversely with the
expression of viral attachment factors on target cells (Boonnak
et al., 2008; Pierson et al., 2007). Analysis of the DC-SIGNR
expression proﬁle of K562-DCSIGNR cells infected in the presence
of enhancing concentrations of antibody (Fig. 4C, Box 2) revealed
a large shift towards lower DC-SIGNR expression (Fig. 4D), reﬂect-
ing the susceptibility to infection of cells expressing low levels of
DC-SIGNR due to Fc-receptor facilitated ADE.
Since this method was effective in analyzing the role of
DC-SIGNR in neutralization, the data from each independent
experiment described in Fig. 2 was reanalyzed using this method.
At several points on each neutralization curve, the DC-SIGNR
expression of infected cells in each sample was compared to the
infected cells in the no-antibody control using chi-squared prob-
ability binning analysis. No signiﬁcant differences were observed
for WNV RVPs and E24 (n¼25), E53 (n¼33), or vaccine candidate
recipient serum (n¼14) on Raji-DCSIGNR cells, or for DENV1 RVPs
and E105 (n¼28) at any concentration tested in the experiment.
Blocking DC-SIGNR does not change the neutralization potency
of anti-WNV antibodies
As a ﬁnal approach, we studied the neutralizing potency of mAb
E24 under conditions where the number of DC-SIGNR molecules
available for WNV attachment was reduced using three different
inhibitors. The mAb 120604 binds the carbohydrate recognition
domain region of DC-SIGNR and has been shown to block
Fig. 2. Neutralizing potency of antibody is independent of target cell attachment factor expression level. Viral immune complexes were generated by pre-incubating WNV
RVPs with serial dilutions of mAb E24, followed by infection of Raji-DCSIGNR cells. Infection was monitored as a function of GFP expression and cells were stained with anti-
DC-SIGNR antibody to measure the surface expression of DC-SIGNR. (A) The neutralization curve for E24 and WNV RVPs on the total population of Raji-DCSIGNR cells is
shown. (B) The expression level of the total cell population stained with anti-DCSIGNR (black) or an isotype control (yellow) antibody is shown. The subset of anti-DC-SIGNR
stained cells that were GFP positive are shown in green. Cells with levels of DC-SIGNR sufﬁcient for infection were divided into categories for analysis based upon expression
(Low, High) as shown by the dotted lines. (C) Dose response neutralization curves are shown for cells with high or low expression of DC-SIGNR. (D) The EC50 value of the mAb
E24 neutralization proﬁle on high and low DC-SIGNR expressing cells was compared between nine independent experiments, and the difference was not statistically
signiﬁcant (p¼0.739). (E and F) Additional neutralization proﬁles of immune complexes were generated by pre-incubating WNV RVPs with serial dilutions of serum from a
vaccine trial volunteer, followed by infection of Raji-DCSIGNR cells (E), or DENV1 RVPs and serial dilutions of the DENV-speciﬁc mAb E105, followed by infection of
Raji-DCSIGNR and Raji-DCSIGN cells (F). Results were analyzed based on high versus low DC-SIGNR or DC-SIGN expression as described for mAb E24 in panels B and C.
Volunteer I shown in (E) is one representative serum sample of eight volunteers tested (Fig. S1). All dose-response curves in this ﬁgure are representative of at least three
independent experiments. Results are normalized to the infectivity obtained in the absence of antibody, and error bars show the standard error of the mean of triplicate wells.
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DCSIGNR cells with mAb 120604 resulted in a dose-dependent
inhibition of WNV RVP infection (EC50¼2.3109 M, n¼2). Like-
wise, pre-treatment of Raji-DCSIGNR cells with glucose or mannose
blocks WNV RVP infection by competing for binding to the carbo-
hydrate recognition domain (EC50¼8.1103 M, n¼2 and
EC50¼3.5103 M, n¼3). Raji-DCSIGNR cells were incubated with
each of these inhibitors at a concentration that corresponds roughly
to the EC50, followed by use in neutralization studies with mAb E24.
As a control, cells were also incubated in the presence of each
inhibitor at a level shown in our studies not to block WNV RVP
entry. A comparison of the potency of E24 in the presence of
inhibitory and non-inhibitory concentrations of mAb 120604,
glucose, or mannose failed to identify an impact of treatments that
functionally reduce the number of DC-SIGNR molecules on Raji cells
(Fig. 5).
The efﬁciency of antibody-mediated neutralization has been
shown in several contexts to vary when assayed using different
cellular substrates (Kjelle´n, 1985; Outlaw et al., 1990). For exam-
ple, studies with a panel of mAbs to La Crosse virus show marked
differences in the protective capacity of different antibodies based
upon the cell type used in the assay (Grady and Kinch, 1985).
In addition, WNV-reactive antibodies have been described that
neutralize infection in a cell type-dependent manner via unknown
mechanisms (Oliphant et al., 2006). Several studies with inﬂuenza
A suggest neutralization potency is modulated by the efﬁciency of
virus attachment to cells (Hensley et al., 2009; Yewdell et al.,
1986). This raises the intriguing possibility that the neutralization
activity of anti-ﬂavivirus antibodies might be impacted by factorsthat control the efﬁciency of virus infection of target cells.
Evaluating this possibility is challenging in light of an incomplete
understanding of factors involved in the attachment and entry of
these viruses into cells. To date, only a small number of cellular
factors that modulate the efﬁciency of ﬂavivirus attachment and
entry into cells have been characterized; none of these have been
shown to be broadly necessary and sufﬁcient for infection among
permissive cell types (Anderson, 2003).
DC-SIGN and DC-SIGNR are related c-type lectins which directly
bind virus particles and promote more efﬁcient infection (Davis
et al., 2006a). In this study, we investigated how changes in
expression of these attachment factors (which in turn control the
efﬁciency of virus binding and infection) modulate antibody-
mediated neutralization. Using several complementary approaches
and two different cell types, we found that changes in the
expression of DC-SIGN or DC-SIGNR do not modulate detectable
changes in the neutralizing activities of ﬂavivirus-reactive anti-
bodies. These results suggest the fate of the virion is determined by
the number of antibodies bound to the virus particle before it
contacts the target cell. Thus, changes in the expression of cellular
receptors are not likely to be mechanistically responsible for the
cell-type dependent neutralization observed for some viruses.
The studies presented within were limited to cell types upon
which the cellular attachment structure was deﬁned and could be
manipulated; the cellular factors involved in attachment to many
cell substrates traditionally used in ﬂavivirus neutralization studies
has not yet been established. The functional properties of ﬂavivirus
reactive antibodies on cells expressing both DC-SIGNR (or
DC-SIGN) and an Fc-receptor reﬂect an overlay of neutralizing
Fig. 3. Neutralizing potency of antibodies to all three domains of the E protein are unaffected by the cellular expression of attachment factor. An inducible DC-SIGNR-
expressing cell line was generated using Jurkat T cells. The cells do not express DC-SIGNR and are not permissive to infection, but can become infected as a function of
DC-SIGNR expression when tetracycline is added. (A) Cells were incubated with the indicated amount of tetracycline for 36 h and either stained with anti-DCSIGNR (black)
or infected with RVPs and monitored for infection (red) as described in the text. Axis scaling was selected to place maximum DC-SIGNR expression and maximum infection
at approximately the same level. (B) Jurkat-DCSIGNR cells were incubated with tetracycline for 36 h to generate high, medium, or low DC-SIGNR expression. Immune
complexes were generated by pre-incubating WNV RVPs with mAbs speciﬁc for epitopes in domain III (C), domain II (D), and domain I (E) of the WNV E protein or serum
from a vaccine trial volunteer (F), followed by infection of target cells. After 48 h, cells were monitored for infection. Neutralization curves are normalized to the infectivity
obtained in the absence of antibody and are representative of at least two independent experiments. Error bars show the standard error of the mean of triplicate wells.
Fig. 4. Antibody protects cells from infection independently of their attachment factor expression level. Immune complexes were generated by pre-incubating WNV RVPs
with serial dilutions of mAb E24, followed by infection of Raji-DCSIGNR cells (FcR) (A and B) and K562-DCSIGNR cells (þFcR) (C and D). Infection was monitored after
48 h as a function of GFP expression using ﬂow cytometry. (A and C) Neutralization dose-response curves are shown normalized to the infectivity obtained in the absence
of antibody. Non-neutralizing (Box 1, blue) and neutralizing (Box 2, orange) concentrations of E24 were used in (B) and (D). (B and D) Cells were infected with immune
complexes generated at the E24 concentrations shown boxed in (A) and (C). Cells were stained with anti-DC-SIGNR antibody, and DC-SIGNR expression of the infected
(GFP positive) cells is shown.
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Fig. 5. Neutralizing potency of antibody to WNV is not affected by blocking attachment factor on target cells. WNV infection of Raji-DCSIGNR cells can be inhibited by
blocking virus engagement of DC-SIGNR with the mAb 120604 (A), glucose (B), or mannose (C). Cells were incubated in the presence of titrations of the indicated DC-SIGNR
blocking agent, followed by infection with WNV RVPs (left panels). Non-inhibitory (Box 1, orange) and inhibitory (Box 2, green) concentrations correspond to the levels
used in the panels to the right. Immune complexes were generated by pre-incubating WNV RVPs with serial dilutions of mAb E24, followed by infection of Raji-DCSIGNR
cells that had been pre-incubated with the indicated DC-SIGNR blocking agent (right panels). Results are normalized to the infectivity obtained in the absence of antibody
or blocking agent and are representative of at least three independent experiments. Error bars show the standard error of the mean of triplicate wells.
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(Boonnak et al., 2008; Pierson et al., 2007). While extending our
studies to primary cell types that are targets of virus infection
in vivo (e.g. DC-SIGNþ dendritic cells) (Tassaneetrithep et al.,
2003; Wu et al., 2000) would have been interesting, these experi-
ments are complicated by the presence of Fc-receptors capable of
enhancing viral infection, particularly when low levels of attach-
ment factor are present. As the requirements for ﬂavivirus entry
are better understood, the contribution of distinct cellular factors
to the effect of antibodies will undoubtedly become more clear.Materials and methods
Maintenance of cell lines
K562 cells were grown in RPMI-1640 medium (Invitrogen)
supplemented with 10% heat-inactivated fetal bovine serum (FBS)(HyClone) and 50 U/ml penicillin–streptomycin (PS) (complete
RPMI). Media used for the culture of a K562 line that stably
expresses DC-SIGNR was supplemented with 10 mg/ml blasticidin
(Invitrogen). Raji and Raji-DCSIGNR cell lines were cultured in
complete RPMI. The inducible Jurkat-DCSIGNR cell line was
maintained in RPMI supplemented with 7% FBS, 50 U/ml PS,
5 mg/ml blasticidin, and 1000 mg/ml geneticin (Invitrogen). HEK-
293T cells were passaged in Dulbecco’s modiﬁed Eagle medium
(DMEM) (Invitrogen) supplemented with 10% FBS and 50 U/ml PS.
All cell lines were maintained at 37 1C in the presence of 7% CO2.
Human immune sera
Serum from recipients of a candidate WNV DNA vaccine was
obtained for use in neutralization studies. A phase I single-site,
open-label clinical study (NCT ID: NCT00106769) to evaluate the
safety and tolerability of a recombinant nucleic acid vaccine has
been described (Martin et al., 2007). The protocol and conduct
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of the US Department of Health and Human Services and was
approved by the NIAID Intramural Institutional Review Board.
Sera from eight subjects was collected at 12 weeks post-ﬁnal
vaccination and studied for neutralizing activity.
Production of a Jurkat cell line that can be induced to express
DC-SIGNR
A Jurkat T cell line was constructed to express DC-SIGNR under
the control of a tetracycline inducible CMV promoter using the
T-REx system (Invitrogen). Brieﬂy, the coding sequence of human
DC-SIGNR was cloned into the pT-REx-DEST30 vector by recom-
bination using a previously described pDONR221 entry clone
(Davis et al., 2006b). The resulting expression clone, pDC-
SIGNR-EXP30, was electroporated into 1.5106 T-REx Jurkat cells
in 160 ml of Buffer SF (divided among eight wells) using the
Amaxa 96-well shuttle nucleofection system (Lonza) and program
CM-150. Transfected cells were selected by repeated passage in
complete RPMI containing 5 mg/ml blasticidin and 1000 mg/ml
geneticin (Invitrogen). Individual clones were isolated by limiting
dilution.
Production of WNV and DENV reporter virus particles
Pseudo-infectious reporter virus particles (RVP) were pro-
duced by transfection of HEK-293T cells with DNA plasmids
encoding the structural genes and a WNV sub-genomic replicon
as described (Pierson et al., 2006; Pierson et al., 2007). Brieﬂy, a
mixture (1:3 by mass) of two plasmids encoding a GFP-expressing
WNV replicon (pWNIIrepGZ) and the WNVI (NY99) or DENV1
(Western Paciﬁc-74) structural genes were transfected into HEK-
293T cells using Lipofectamine LTX (Invitrogen) according to the
manufacturer’s speciﬁcations. The transfection media was replaced
after four hours with a low glucose formulation of DMEM supple-
mented with 10% FBS and 50 U/ml PS. RVPs were collected at
48 hours, aliquoted, and stored at 80 1C until use.
Neutralization of reporter virus particles
Neutralization of WNV and DENV RVPs was performed as
previously described (Dowd et al., 2011; Nelson et al., 2008;
Pierson et al., 2007). Brieﬂy, RVPs were incubated with serial
dilutions of antibody or human serum for one hour at 37 1C and
then added to cells (total infection volume of 300ul in each well of
a 96-well plate). Infected cells were incubated for 48 h at 37 1C in
7% CO2. Infected cells were ﬁxed with 2% paraformaldehyde (PFA)
and then enumerated by analysis of GFP expression using a
FACSCalibur ﬂow cytometer (BD Biosciences). Neutralization
potency (EC50) was estimated by a least squared minimization
non-linear regression analysis using Prism software (GraphPad).
Quantiﬁcation of DC-SIGNR expression by ﬂow cytometry
The expression of DC-SIGNR was measured by ﬂow cytometry
using phycoerythrin-conjugated mAbs (R&D Systems clone
120604). Cells were stained, washed once in cold Dulbecco’s
phosphate-buffered saline (PBS), and ﬁxed with 2% PFA in PBS.
The number of DC-SIGNR molecules expressed on each cell was
estimated by comparison to a standard curve generated using
Quantum Simply Cellular beads that have a known number of
antibody binding sites (Bangs Laboratories, Inc.) processed in
parallel. Use of this standard curve assumes each DC-SIGNR
molecule is engaged by a single antibody molecule. Beads and
cells were collected using a FACSCaliber cytometer (BD
Biosciences).Chi-squared probability binning analysis
DC-SIGNR expression proﬁles of infected cells (GFP positive
cells) were compared between samples where antibody was pre-
sent or absent during infection using the probability chi-squared
binning analysis tool in the FlowJo software package (Tree Star,
Inc.). This allows a comparison of two cell populations of different
sizes without biasing towards effects at the tails of the distribu-
tion. Brieﬂy, the control population (infected cells without anti-
body present) was divided into approximately 300 gates with
roughly equal numbers of cells per gate. The total number of cells
in each gate was divided by the total number of cells in the
sample, and the resulting metric was recorded as the value for
that gate. The same gates used in the control population were
then applied to the experimental population (infected in the
presence of antibody), and the process was repeated. For each
gate, the two population test metrics were compared by tradi-
tional chi-squared analysis. The resulting statistic T(w) is analo-
gous to a t-score, and can be used to ﬁnd the probability that two
populations could be drawn from the same sample.Acknowledgments
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